Using prognosis to guide early detection and treatment selection in non-metastatic prostate cancer.

Over recent years there has been an increasing awareness that our ideas on the lethality of primary non-metastatic prostate cancer may need to change. This concept has emerged from a number of different sources including randomised controlled trials, reports from mature active surveillance programmes and prognostic modelling work in large populations (1-2).

The evidence suggests that for many men without metastatic disease (85% of all presentations from the recent UK National Prostate Cancer Audit) tumours will evolve slowly and will not translate into cancer related mortality, at least, not within the first 10-15 years of its natural history. This article is protected by copyright. All rights reserved.

BJU international. 2018 Nov 30 [Epub ahead of print]

Vincent Gnanapragasam, Tristan Barrett, Charlie Massie, Simon Pacey, Anne Warren

Translational Prostate Cancer Group, CRUK Cambridge Cancer Centre, Cambridge, United Kingdom.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe